Chromedx Corp (MNLIF) 0.0980 $MNLIF
ChroMedX Announces Appointment of Ash Kaushal as President and CEO
ACCESSWIRE - Tue Jul 26, 5:20AM CDT
TORONTO, ONTARIO / ACCESSWIRE / July 26, 2016 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and Point-of-care Testing (POCT) technologies is pleased to announce the appointment of Ash Kaushal as the Company's new President and CEO, effective immediately.
ChroMedX Reports on HemoPalm Development
ACCESSWIRE - Fri Apr 29, 3:30PM CDT
TORONTO, ON / ACCESSWIRE / April 29, 2016 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company", a developer of in vitro diagnostics and Point-of-care Testing technologies is pleased to report on the Company's HemoPalm development programme.
ChroMedX Corp. Engages Conductive Technologies Inc. for Biosensor Development Programme
ACCESSWIRE - Wed Apr 20, 3:30PM CDT
TORONTO, ON / ACCESSWIRE / April 20, 2016 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company", a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of Conductive Technologies Inc. (CTI) of York, Pennsylvania to assist with biosensor development on the Company's HemoPalm technology.
ChroMedX Completes Proof-of-Concept CO-oximetry and Bilirubin Prototype Development
ACCESSWIRE - Fri Dec 11, 3:21PM CST
TORONTO, ON / ACCESSWIRE / December 11, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company", a developer of in vitro diagnostics and point-of-care testing (POCT) devices is pleased to report the development of a proof-of-concept prototype of the Company's HemoPalm(TM) analyzer and associated cartridge for measuring CO-oximetry and bilirubin*.
ChroMedX Engages Hochuen International Corp. for Improved Prototype Cartridge Production
ACCESSWIRE - Tue Dec 08, 3:17PM CST
TORONTO, ON / ACCESSWIRE / December 8, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company", a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that it has engaged Hochuen International Corp. to produce an enhanced version of its prototype HemoPalm cartridges.
ChroMedX Awarded a United States Patent on its Ultra Filtration Technology - Video News Alert on InvestmentPitch.com
Newsfile Corp - Tue Oct 20, 12:00PM CDT
full story)
ChroMedX Corp. Announces Closing of First Tranche of Private Placement
ACCESSWIRE - Fri Oct 16, 5:48PM CDT
TORONTO, ON / ACCESSWIRE / October 16, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company", a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement (the "Offering", pursuant to which the Company issued and sold an aggregate of 1,750,000 units (each, a "Unit" of the Company at a price of CDN$0.20 per Unit for aggregate gross proceeds of CDN$350,000. Each Unit is comprised of one common share of the Company (a "Common Share" and one Common Share purchase warrant (a "Warrant", each Warrant entitling the holder thereof to acquire one Common Share at a price of $0.30 for a period of twenty-four (24) months from the closing date.
ChroMedX Corp. Awarded New United States Patent on Ultra Filtration Technology
ACCESSWIRE - Wed Oct 14, 3:15PM CDT
TORONTO, ON / ACCESSWIRE / October 14, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company", a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded a United States patent on its Ultra Filtration technology.
ChroMedX Corp. Announces Private Placement of Units
ACCESSWIRE - Fri Oct 09, 7:21PM CDT
TORONTO, ON / ACCESSWIRE / October 9, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company", a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it intends to complete a non-brokered private placement (the "Offering" for gross proceeds of up to CDN$800,000 through the issuance of up to 4,000,000 units (each a "Unit" at a price of CDN$0.20 per Unit. Each Unit will be comprised of one common share of the Company (a "Common Share" and one Common Share purchase warrant (a "Warrant", each Warrant entitling the holder thereof to acquire one Common Share at a price of $0.30 for a period of twenty-four (24) months from the closing date.
ChroMedX Corp. Awarded Two New Patents on Ultra-Filtration Technology
ACCESSWIRE - Wed Sep 30, 3:12PM CDT
TORONTO, ON / ACCESSWIRE / September 30, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company", a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded two additional Canadian patents on its Automated Ultra Filtration (AUF) technology.
ChroMedX Callaborates with Biointerfaces Institute and Receives Grant
Newsfile Corp - Wed Sep 16, 3:08PM CDT
full story)
ChroMedX Announces Appointment of Ash Kaushal as President and CEO
ACCESSWIRE - Tue Jul 26, 5:20AM CDT
TORONTO, ONTARIO / ACCESSWIRE / July 26, 2016 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and Point-of-care Testing (POCT) technologies is pleased to announce the appointment of Ash Kaushal as the Company's new President and CEO, effective immediately. ChroMedX Reports on HemoPalm Development
ACCESSWIRE - Fri Apr 29, 3:30PM CDT
TORONTO, ON / ACCESSWIRE / April 29, 2016 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and Point-of-care Testing technologies is pleased to report on the Company's HemoPalm development programme. ChroMedX Corp. Engages Conductive Technologies Inc. for Biosensor Development Programme
ACCESSWIRE - Wed Apr 20, 3:30PM CDT
TORONTO, ON / ACCESSWIRE / April 20, 2016 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of Conductive Technologies Inc. (CTI) of York, Pennsylvania to assist with biosensor development on the Company's HemoPalm technology. ChroMedX Completes Proof-of-Concept CO-oximetry and Bilirubin Prototype Development
ACCESSWIRE - Fri Dec 11, 3:21PM CST
TORONTO, ON / ACCESSWIRE / December 11, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and point-of-care testing (POCT) devices is pleased to report the development of a proof-of-concept prototype of the Company's HemoPalm(TM) analyzer and associated cartridge for measuring CO-oximetry and bilirubin*. ChroMedX Engages Hochuen International Corp. for Improved Prototype Cartridge Production
ACCESSWIRE - Tue Dec 08, 3:17PM CST
TORONTO, ON / ACCESSWIRE / December 8, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that it has engaged Hochuen International Corp. to produce an enhanced version of its prototype HemoPalm cartridges. ChroMedX Awarded a United States Patent on its Ultra Filtration Technology - Video News Alert on InvestmentPitch.com
Newsfile Corp - Tue Oct 20, 12:00PM CDT
full story)
ChroMedX Corp. Announces Closing of First Tranche of Private Placement
ACCESSWIRE - Fri Oct 16, 5:48PM CDT
TORONTO, ON / ACCESSWIRE / October 16, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement (the "Offering", pursuant to which the Company issued and sold an aggregate of 1,750,000 units (each, a "Unit" of the Company at a price of CDN$0.20 per Unit for aggregate gross proceeds of CDN$350,000. Each Unit is comprised of one common share of the Company (a "Common Share" and one Common Share purchase warrant (a "Warrant", each Warrant entitling the holder thereof to acquire one Common Share at a price of $0.30 for a period of twenty-four (24) months from the closing date. ChroMedX Corp. Awarded New United States Patent on Ultra Filtration Technology
ACCESSWIRE - Wed Oct 14, 3:15PM CDT
TORONTO, ON / ACCESSWIRE / October 14, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded a United States patent on its Ultra Filtration technology. ChroMedX Corp. Announces Private Placement of Units
ACCESSWIRE - Fri Oct 09, 7:21PM CDT
TORONTO, ON / ACCESSWIRE / October 9, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it intends to complete a non-brokered private placement (the "Offering" for gross proceeds of up to CDN$800,000 through the issuance of up to 4,000,000 units (each a "Unit" at a price of CDN$0.20 per Unit. Each Unit will be comprised of one common share of the Company (a "Common Share" and one Common Share purchase warrant (a "Warrant", each Warrant entitling the holder thereof to acquire one Common Share at a price of $0.30 for a period of twenty-four (24) months from the closing date. ChroMedX Corp. Awarded Two New Patents on Ultra-Filtration Technology
ACCESSWIRE - Wed Sep 30, 3:12PM CDT
TORONTO, ON / ACCESSWIRE / September 30, 2015 / ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"
, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded two additional Canadian patents on its Automated Ultra Filtration (AUF) technology. ChroMedX Callaborates with Biointerfaces Institute and Receives Grant
Newsfile Corp - Wed Sep 16, 3:08PM CDT
full story)
